Shares of West Pharmaceutical Services (WST) are soaring 9.41% in Thursday's trading session following the company's impressive third-quarter 2025 results and an upward revision of its full-year guidance. The medical equipment maker's performance has been bolstered by strong demand for its components used in GLP-1 weight-loss and diabetes drugs.

West Pharmaceutical reported third-quarter adjusted earnings per share of $1.96, significantly beating the analyst consensus estimate of $1.68. Net sales for the quarter reached $804.6 million, up 7.7% year-over-year and surpassing the expected $787.92 million. The strong performance was driven by double-digit growth in High-Value Product Components, particularly those used in GLP-1 products, and increased demand for self-injection devices for obesity and diabetes treatments.

In light of these robust results, West Pharmaceutical has raised its full-year 2025 guidance. The company now expects adjusted earnings per share between $7.06 and $7.11, up from the previous forecast of $6.65 to $6.85. Annual sales projections have also been increased to a range of $3.06 billion to $3.07 billion, reflecting ongoing momentum in the company's proprietary and contract-manufacturing units. This positive outlook, coupled with the strong Q3 performance, has fueled investor optimism, leading to the significant stock price surge.